drugset / Trial / NCT06857279
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Timeline
- Start
- 2025-04-22
- Primary completion
- 2027-12-30
- Completion
- 2029-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HLX43 | Other / unclassified | — | Intravenous |
| Subject | PIMURUTAMAB | Monoclonal antibody | — | — |
| Subject | Serplulimab | Monoclonal antibody | — | — |